Alerts will be sent to your verified email
Verify EmailDRREDDY
Dr. Reddy's Lab
|
Glenmark Pharma
|
Gland Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
Global DMFs filed
|
1143.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
348.0 . | 13.0 . | 349.0 . |
Number of ANDA's Approved By USFDA
|
262.0 . | 25.0 . | 286.0 . |
Domestic Sales Growth - YoY
|
6.4 % | 11.3 % | n/a |
R&D as a % of Total Sales
|
9.7 % | 8.7 % | 3.7 % |
Financials
|
|||
5 yr Average ROE
|
13.74 % | 11.3 % | 16.21 % |
5yr average Equity Multiplier
|
1.45 | 1.97 | 1.1 |
5yr Average Asset Turnover Ratio
|
0.76 | 0.79 | 0.54 |
5yr Avg Net Profit Margin
|
12.57 % | 7.09 % | 26.8 % |
Price to Book
|
3.76 | 4.49 | 3.42 |
P/E
|
19.06 | 0.0 | 38.64 |
5yr Avg Cash Conversion Cycle
|
68.59 Days | -113.73 Days | 141.92 Days |
Inventory Days
|
75.58 Days | 50.29 Days | 117.9 Days |
Days Receivable
|
103.01 Days | 44.33 Days | 97.99 Days |
Days Payable
|
102.58 Days | 209.82 Days | 98.36 Days |
5yr Average Interest Coverage Ratio
|
30.9 | 4.6 | 245.99 |
5yr Avg ROCE
|
17.57 % | 17.22 % | 21.37 % |
5yr Avg Operating Profit Margin
|
22.4 % | 19.07 % | 39.34 % |
5 yr average Debt to Equity
|
0.16 | 0.62 | 0.0 |
5yr CAGR Net Profit
|
18.24 % | -20.31 % | 0.21 % |
5yr Average Return on Assets
|
9.53 % | 5.67 % | 14.66 % |
Shareholdings
|
|||
Promoter Holding
|
26.65 % | 46.64 % | 57.86 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.09 % | 0.01 % | -0.39 % |
Change in Mutual Fund Holding (3 Yrs)
|
-5.35 % | 7.28 % | 12.81 % |
Dr. Reddy's Lab
|
Glenmark Pharma
|
Gland Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|